reported third-quarter earnings that beat analysts' estimates for the period.
The clinical laboratory testing company reported third-quarter net income of 60 cents a share, compared with 29 cents a share for the year ago period. The five-analyst
First Call/Thomson Financial
consensus estimate called for the company to earn 56 cents a share for the quarter.
Revenue for the latest third quarter came in at $850 million, compared with $615 million a year ago.